Dr. Berman is a renowned physician-scientist and clinical leader with a distinguished track record in translational and clinical research across oncology and mitochondrial disease. As interim Chief Medical Officer, Dr. Berman will oversee all clinical development and medical affairs activities at BPGbio, with a focus on progressing the company’s lead program, BPM31510, currently in planning stages for a registrational trial for Primary CoQ10 Deficiency (PCQD) and in Phase 2b trials for glioblastoma multiforme (GBM). He will also provide guidance on the company’s expanding portfolio in oncology and other rare diseases, ensuring strong scientific and clinical alignment with regulatory and patient community needs.

Dr. Berman is no stranger to BPM31510 or BPGbio. In 2022, while serving as Acting CMO, he spearheaded the initiation and execution of the now fully enrolled Phase 2b trial for GBM. Prior to that, he directed the clinical studies evaluating the safety and efficacy of BPM31510 in the treatment of in situ cutaneous squamous cell carcinoma (SCC).

Currently, Dr. Berman serves as Co-Director of the Center for Clinical and Cosmetic Research in Aventura, FL, where he continues his broad-based clinical research program, including small molecule protection of mitochondrial DNA mutations. He has delivered more than 300 presentations at national and international scientific conferences and authored over 250 peer-reviewed scientific and clinical publications, chapters and books. His work has been recognized with numerous honors, including “Scientist of the Year” Award from Sigma Xi, the Science and Research Honor Society; “Practitioner of the Year” by the Florida Society of Dermatology and Dermatologic Surgery; and inclusion in the U.S. News and World Report’s “Best Doctors”.

Dr. Berman is Professor Emeritus of Dermatology and Dermatologic Surgery at The University of Miami Miller School of Medicine and has served as President of the American Dermatological Association, Vice President and a board member of the American Academy of Dermatology. Dr. Berman is Secretary of the American Cutaneous Oncology Society, and he also founded and served as President of The National Association of Veterans Affairs Dermatologists.

Over his career, Dr. Berman has consulted for numerous biopharmaceutical and medical device companies on drug development, clinical strategy, and commercialization—supporting transactions and programs exceeding US$10 billion in value.